Search results for "Neo adjuvant"

showing 4 items of 4 documents

Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients …

2018

568Background: GAIN-2 compares the effectiveness and safety of a predefined idd regimen (EnPC) vs. a dd regimen with modification of single doses depending on individual hematological and non-hemat...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryNeo adjuvant03 medical and health sciencesRegimen030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicinebusinessPathologicalComplete responseEarly breast cancerJournal of Clinical Oncology
researchProduct

Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial

2021

Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared the effects of high- vs low-to-moderate-intensity exercise with or without additional behavior change support (BCS) on CRF in patients undergoing (neo-)adjuvant cancer treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo-)adjuvant treatment were randomized to high intensity (n = 144), low-to-moderate intensity (n = 144), high intensity with BCS (n = 144) or low…

MaleAnxiety030204 cardiovascular system & hematologyNeo adjuvantlaw.inventionTumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14]0302 clinical medicineRandomized controlled trialBehavior TherapylawNeoplasmsActivities of Daily LivingOrthopedics and Sports MedicineSjukgymnastikPhysiotherapyCancer-related fatigueLicenseFatigueDepressionCreative commonsMiddle AgedVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850Neoadjuvant TherapyExercise TherapyCancer treatmentEndurance TrainingCardiorespiratory FitnessVDP::Medisinske Fag: 700::Helsefag: 800Femalemedicine.symptomColorectal NeoplasmsPsychologybehavior change; cancer‐ related fatigue; endurance training; oncology; resistance trainingmedicine.medical_specialtyBreast NeoplasmsPhysical Therapy Sports Therapy and Rehabilitation03 medical and health sciencesmedicineHumansMuscle StrengthCancer och onkologiResistance trainingProstatic NeoplasmsResistance Training030229 sport sciencesCancer and OncologyQuality of LifeExercise intensityPhysical therapySedentary BehaviorSleep
researchProduct

Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2…

2013

602 Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingly used therapy option for the treatment of recurrent/metastatic breast cancer (MBC). However, limited data on T re-treatment is currently available. Methods: Patients with locally recurrent and/or MBC who received T re-therapy were included in this non-interventional study. Among 232 pts enrolled at 121 sites in Germany, 174 pts (33 locally recurrent disease, 141 MBC) were already sufficiently documented to be analyzed for efficacy of T re-ther…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentLocally advancedNeo adjuvantmedicine.diseaseSurgeryBreast cancerOncologyTrastuzumabHER2 Positive Breast CancerInternal medicinemedicineIn patientAnti her2businessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast canc…

2020

Oncologymedicine.medical_specialtymedicine.anatomical_structureOncologybusiness.industryInternal medicineT cellmedicineHematologyNeo adjuvantbusinessTriple-negative breast cancerImmune therapyAnnals of Oncology
researchProduct